Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health ("Radius") today announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company's novel PTHrP (parathyroid hormone-related protein) analog -- significantly increased bone mineral density (BM...
Project Zero Delay Accelerates Drug's Path to Clinical Trial
HOUSTON and WILMINGTON, Del., Aug. 3 /PRNewswire-FirstCall/ -- A phase I clinical
trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical
development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...
Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
SAN DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first cli...
Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
ANN ARBOR, Mich., July 24 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced that it has initiated a Phase II Clinical
Trial for the Anaconda(TM) AAA (Abdominal Aortic Aneurysm) Stent Graft System in the U.S. The Anaconda system is manufactured by Scotland-based Terumo subs...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that in the TASKi3 Phase 2b clinical
trial in rheumatoid arthritis (RA) patients who had failed to respond to at least one biologic treatment, the group treat...
Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
REDWOOD CITY, Calif., July 22 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC ) today announced that the full results of the PAS-Port system multi-center pivotal trial, known as the EPIC trial, were published in the July issue of the peer-reviewed publication The J ournal ...
R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
TOKYO, July 21 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 17 that as a phase 1 clinical
study on the new compound RK-023 that is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed.
Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
WARSAW, Ind., July 20 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ZMH) today announced that data from a comparative clinical
study conducted by researchers at the Mayo Clinic and the Joint Replacement Surgeons of the Indiana Research Foundation describes the ...
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and heart disease, often in...
Reliv International's GlucAffect(TM) Proven Effective in Clinical Study
Study Shows GlucAffect Reduces Blood Glucose Levels and Promotes Weight Loss
CHESTERFIELD, Mo., July 16 /PRNewswire-FirstCall/ -- A clinical
study published in the journal Phytotherapy Research found that GlucAffect, a nutritional supplement developed by Reliv Inte...
Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
FREMONT, Calif., July 16 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical
research management systems, announced today the availability of new system capabilities to ensure that the cancer center community can fulfill new registration requirements for the U.S. National Cancer ...
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical
Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through ...
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that R788 (fostamatinib disodium) produced significant clinical
improvement in rheumatoid arthritis (RA) patients in the recently completed TASKi2 Phase 2b clinical
trial of ...
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investig...
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
EMERYVILLE, Calif. and HUENENBERG, Switzerland, July 5 /PRNewswire-FirstCall/ -- Alcon, Inc. (NYSE: ACL ) and its partner, NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY ), announced today that Alcon has begun treating patients in a Phase 2 clinical
trial of NovaBay's patented lead Aganocide(R)...
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately
held drug development company with its headquarters in Turku, Finland,
announced positive results from its Phase IIa clinical
trial of ProtoCure(TM)
emulsion cream, the company's novel topical drug for dermatology. This
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical
trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo act...
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
AMSTERDAM, The Netherlands, June 30 /PRNewswire/ --
- "Study Could Have Major Impact on the Decision-Making Process With
Respect to Infertility Treatment"
New data from an economic analysis presented today at this year's
European Society of Human Reproduction and Embryology (ESHR...
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
CHIPPENHAM, England and TOKYO, June 29 /PRNewswire/ --
- Study Triggers $7.5m Milestones for Both Companies
Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura
Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III
clinical study by Novartis, ...
Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
GORDONSVILLE, Va., June 24 /PRNewswire/ -- PBM Products, LLC, a leading infant formula company that supplies store-brand infant formulas to Walmart, Sam's Club, Target, Kroger, CVS, Walgreens, and other retailers, has partnered with the University of Virginia (U.Va.) to conduct clinical
Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
SAN DIEGO, June 24 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical
trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with...
West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
Collaboration will test remote wireless monitoring to prevent hospital readmissions for heart failure
SAN DIEGO, June 24 /PRNewswire-USNewswire/ -- The West Wireless Health Institute (WWHI), one of the world's first medical research organizations dedicated to advancing health and well-being t...
Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
--Integrated human AME studies comply with recent FDA guidance for earlier testing--
PRINCETON, N.J., June 23 /PRNewswire/ -- Covance Inc. today announced its integrated radiolabeled clinical
pharmacology studies in compliance with Food and Drug Administration (FDA) guidance on Metabol...
DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture (EDC) Clinical Trial Survey
eClinical Forum partners with TechTeam Global to complete important new study
SAN DIEGO, June 22 /PRNewswire-FirstCall/ -- Attendees at the 45th Annual Meeting of the Drug Information Association (DIA), held June 21-25 in San Diego, Calif., will have a chance to respond to an in-depth, global su...
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced results from a pivotal clinical
trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show th...
New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
DUBLIN, June 18 /PRNewswire-FirstCall/ -- According to a report issued
today, drug safety leaders in pharmaceutical and biotechnology companies
recognise the need to increase resources, either internally or through
partnerships, to comply with the safety regulations recently issued by the
ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
SEATTLE, Washington, and LEIDEN, The Netherlands, June 18 /PRNewswire/ --
ProFibrix B.V. today announced the start of the company's Phase II clinical
trial for Fibrocaps(TM), the company's lead topical Hemostat product, with
the successful treatment of the first patients for mild to moderate b...
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company
FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the f...
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
Phase 3 PROTEGE ENCORE Clinical
ROCKVILLE, Md. and INDIANAPOLIS, June 16 /PRNewswire/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical
New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
Bill would remove financial penalties for participating in research studies
BETHESDA, Md., June 15 /PRNewswire-USNewswire/ -- New legislation introduced today would allow patients with rare diseases to participate in clinical
drug studies without losing their eligibility for government health...
When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research
Femmenessence: Proven to Regulate Hormone Levels in Women
SAN FRANCISCO, June 12 /PRNewswire/ -- Women approaching and exiting menopause are in a bind. As hormone levels fluctuate and decline, they experience a range of uncomfortable symptoms that can include hot flashes, night sweats, mood d...
Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
First-In-Class Human Collagen Technology Used in Cranial Surgical Procedures
EATONTOWN, N.J., June 10 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE ), a leader in the emerging field of biologic products for regenerative healing, announced today that it has completed enrollment for...
Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that a summary of the pixantrone Phase III clinical
data that were presented at American Society of Clinical
Oncology (ASCO) 2009 Annual Meeting on June 1, 2009 is now available at Cli...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively Assessed in Large Outcomes Trial
NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced results from a meta-analysis of ...
Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Studies Advocate Blood Conservation and Appropriate Indicators for Transfusion
IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that two new studies - ...
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams (mg) Dosing over Five to Seven Days of Treatment
SAN DIEGO, June 8 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 2 clinical
trial evaluating the safety and effic...
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH ), a medical technology company testing its proprietary percutaneous hepatic perfusion (PHP(TM)) system for the treatment of cancers of the liver, announced today that it has achieved the seventy-five percent enroll...